logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hyun Cheol Chung

Songdang Institute for Cancer Research
H指数:86
被引数:5.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups” [Cancer Lett. 623, (2025) 217718]

勘误：“Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups” [Cancer Lett. 623, (2025) 217718]

Cancer Letters
IF10.1
2025-06-030
PRE
Lee, Choong-kun; Park, Sejung; Lee, Yaeji; Yun, Choa; Hong, Moonki; Nam, Chung Mo; Chung, Hyun Cheol; Rha, Sun Young
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma

KEYNOTE-811研究的III期最终总生存数据，该研究评估了帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性、不可切除或转移性胃/胃食管结合部腺癌。

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J-P.; Weber, P. E. Yanez; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Mahave, M.; van Cutsem, E.; Tabernero, J.; Xu, L.; Sharan, K. P.; Bhagia, P.; Janjigian, Y. Y.
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study

Lenvatinib联合pembrolizumab治疗先前治疗的晚期三阴性乳腺癌患者: 来自LEAP-005 2期研究的三阴性乳腺癌队列的结果

CANCER
IF5.1
2024-06-211
OAAI
Chung, Hyun Cheol; Saada-Bouzid, Esma; Longo, Federico; Yanez, Eduardo; Im, Seock-Ah; Castanon, Eduardo; Desautels, Danielle N.; Graham, Donna M.; Garcia-Corbacho, Javier; Lopez, Juanita; Dutcus, Corina; Okpara, Chinyere E.; Ghori, Razi; Jin, Fan; Groisberg, Roman; Korakis, Iphigenie
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial (vol 42, pg 145, 2024)

CXCR2拮抗剂navarixin联合pembrolizumab治疗晚期实体瘤: 一项2期随机试验 (第42卷，145页，2024)

INVESTIGATIONAL NEW DRUGS
IF2.7
2024-05-200
OAAI
Armstrong, Andrew J.; Geva, Ravit; Chung, Hyun Cheol; Lemech, Charlotte; Miller Jr, Wilson H.; Hansen, Aaron R.; Lee, Jong-Seok; Tsai, Frank; Solomon, Benjamin J.; Kim, Tae Min; Rolfo, Christian; Giranda, Vincent; Ren, Yixin; Liu, Fang; Kandala, Bhargava; Freshwater, Tomoko; Wang, Judy S.
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

曲妥珠单抗deruxtecan治疗HER2-positive晚期胃癌: 随机2期DESTINY-Gastric01试验的探索性生物标志物分析

NATURE MEDICINE
IF50
2024-05-142
OAAI
Shitara, Kohei; Bang, Yung-Jue; Iwasa, Satoru; Sugimoto, Naotoshi; Ryu, Min-Hee; Sakai, Daisuke; Chung, Hyun Cheol; Kawakami, Hisato; Yabusaki, Hiroshi; Sakamoto, Yasuhiro; Nishina, Tomohiro; Inaki, Koichiro; Kuwahara, Yusuke; Wada, Naoya; Suto, Fumitaka; Arita, Takeo; Sugihara, Masahiro; Tsuchihashi, Zenta; Saito, Kaku; Kojima, Akihito; Yamaguchi, Kensei
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

CXCR2拮抗剂navarixin联合pembrolizumab治疗晚期实体瘤: 一项2期随机试验

INVESTIGATIONAL NEW DRUGS
IF2.7
2024-02-0718
OAAI
Armstrong, Andrew J.; Geva, Ravit; Chung, Hyun Cheol; Lemech, Charlotte; Miller Jr., Wilson H.; Hansen, Aaron R.; Lee, Jong-Seok; Tsai, Frank; Solomon, Benjamin J.; Kim, Tae Min; Rolfo, Christian; Giranda, Vincent; Ren, Yixin; Liu, Fang; Kandala, Bhargava; Freshwater, Tomoko; Wang, Judy S.
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Pembrolizumab联合曲妥珠单抗和化疗治疗HER2-positive胃或胃食管交界处腺癌: 来自3期KEYNOTE-811随机安慰剂对照试验的中期分析

LANCET
IF88.5
2023-12-01120
PRE
Janjigian, Yelena Y.; Kawazoe, Akihito; Bai, Yuxian; Xu, Jianming; Lonardi, Sara; Metges, Jean Phillipe; Yanez, Patricio; Wyrwicz, Lucjan S.; Shen, Lin; Ostapenko, Yuriy; Bilici, Mehmet; Chung, Hyun Cheol; Shitara, Kohei; Qin, Shu-Kui; Van Cutsem, Eric; Tabernero, Josep; Li, Kan; Shih, Chie-Schin; Bhagia, Pooja; Rha, Sun Young
Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response

先前使用抗生素通过改变肠道微生物组和全身免疫反应来破坏晚期胃癌的anti-PD-1反应

CELL REPORTS MEDICINE
IF10.6
2023-11-015
OAAI
Kim, Chang Gon; Koh, June-Young; Shin, Su-Jin; Shin, Ji-Hee; Hong, Moonki; Chung, Hyun Cheol; Rha, Sun Young; Kim, Hyo Song; Lee, Choong-Kun; Lee, Ji Hyun; Han, Yejeong; Kim, Hyoyong; Che, Xiumei; Yun, Un-Jung; Kim, Hyunki; Kim, Jee Hung; Lee, Seo Young; Park, Su Kyoung; Park, Sejung; Kim, Hyunwook; Ahn, Jin Young; Jeung, Hei-Cheul; Lee, Jeong Seok; Nam, Young-Do; Jung, Minkyu
The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

pembrolizumab加曲妥珠单抗和化疗治疗HER2转移性胃或胃食管交界处 (mG/GEJ) 腺癌的III期，随机，双盲，安慰剂对照的主题811研究

ANNALS OF ONCOLOGY
IF65.4
2023-11-010
PRE
Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J-P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Qin, S.; van Cutsem, E.; Tabernero, J.; Li, K.; Shih, C-S.; Bhagia, P.; Janjigian, Y. Y.
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study

nivolumab和紫杉醇二线化学免疫治疗免疫相关生物标志物富集的晚期胃癌: 一项多中心Ib/II期研究

GASTRIC CANCER
IF5.1
2023-10-315
PRE
Lee, Choong-kun; Lee, Jii Bum; Park, Se Jung; Che, Jingmin; Kwon, Woo Sun; Kim, Hyo Song; Jung, Minkyu; Lee, Seulkee; Park, Sook Ryun; Koo, Dong-Hoe; Lee, Hyun Woo; Bae, Woo Kyun; Jeung, Hei-Cheul; Hwang, In Gyu; Kim, Hyunki; Nam, Chung Mo; Chung, Hyun Cheol; Rha, Sun Young
Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
ANNALS OF ONCOLOGY
IF65.4
2023-10-013
OA
Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J-P.; Weber, P. E. Yanez; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Qin, S.; Van Cutsem, E.; Tabernero, J.; Li, K.; Shih, C-S.; Bhagia, P.; Rha, S. Y.
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial

基因表达特征与pembrolizumab与紫杉醇治疗晚期胃癌的临床结局之间的关联: 来自随机，对照，III期KEYNOTE-061试验的探索性分析

JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2023-06-307
OAAI
Shitara, Kohei; Di Bartolomeo, Maria; Mandala, Mario; Ryu, Min-Hee; Caglevic, Christian; Olesinski, Tomasz; Chung, Hyun Cheol; Muro, Kei; Goekkurt, Eray; McDermott, Raymond S.; Mansoor, Wasat; Wainberg, Zev A.; Shih, Chie-Schin; Kobie, Julie; Nebozhyn, Michael; Cristescu, Razvan; Cao, Z. Alexander; Loboda, Andrey; Ozguroglu, Mustafa

研究方向

暂未获取到该数据
S
Sun Young Rha
H 指数:86论文数:1,323被引数:3.4万
H
Hei‐Cheul Jeung
H 指数:34论文数:239被引数:3,641
S
Sung Hoon Noh
H 指数:76论文数:914被引数:2.2万
J
Joong Bae Ahn
H 指数:43论文数:353被引数:7,506
W
Woo Sun Kwon
H 指数:17论文数:112被引数:889
H
Hyo Song Kim
H 指数:40论文数:301被引数:5,182
J
Jae Kyung Roh
H 指数:34论文数:290被引数:7,760
M
Minkyu Jung
H 指数:32论文数:243被引数:3,535
T
Tae Soo Kim
H 指数:22论文数:108被引数:1,431
K
Kohei Shitara
H 指数:79论文数:1,129被引数:3.5万